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Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain,
and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling
prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens.
These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction
of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T
consistingofautologousperipheralbloodmononuclearcellsincludingAPCs,whichwerepre-exposedinvitrotothefusionprotein
PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistent prostate cancer. In April 2010,
sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.
1.Introduction
Prostatecancer(PCa)representsthemostcommonnoncuta-
neous cancer and the second leading cause of cancer-related
deaths in the United States with an estimated incidence of
192,280 cases and an estimated number of 27,360 deaths in
2009 [1]. In Europe, PCa is also the most frequent cancer
diagnosed in men with an estimated number of 345,900
cases in 2006 [2]. Most of the patients are diagnosed with
organ-conﬁned disease, for which radical prostatectomy,
radiotherapy, and brachytherapy are eﬀective treatment
modalities [3, 4]. Active surveillance, which includes active
monitoring of the disease and start of treatment at pre-
deﬁned thresholds for progression, represents an alternative
since most of these tumors would never become of vital
clinical importance if they had not been detected. Although
the majority of patients are successfully treated with radical
prostatectomy or radiation therapy, approximately 30% of
patients develop recurrent disease [5].
Androgen deprivation represents an eﬀective treatment
modality for recurrent PCa [3, 4]. Bisphosphonates can
increase bone mineral density and reduce the risk of
bone fractures, which are typical side eﬀects of androgen
deprivation therapy [6]. Similar eﬀects are expected for the
treatment with denosumab, a monoclonal antibody against
receptor activator of NF-kappaB ligand, which acts as a key
mediator forosteoclast function, activation, and survival[7].
Therapeutic options for patients with progressive disease
under androgen deprivation therapy comprise secondary
hormonal manipulation and nonhormonal therapy such
as chemotherapy [3]. In the management of metastatic
hormone-refractory PCa (HRPC), chemotherapy with doc-
etaxel serves as reference treatment due to the demonstrated
signiﬁcantsurvivalbeneﬁt[8,9].InpatientswithHRPC,bis-
phosphonates are useful for the treatment of skeletal compli-
cations and pain relief thereby improving quality of life and
also providing a suitable medication for palliative care [3].
Despite of the therapeutic beneﬁt of these approaches
and the achieved prolongation of overall survival, additional
treatment strategies are needed to prevent progression from
localized to advanced disease and to furtherimprove survival
outcomes for patients with advanced PCa.2 Clinical and Developmental Immunology
2. The Important Role of DendriticCells in
Antitumor Immunity
Dendritic cells (DCs) are professional antigen-presenting
cells (APCs), which display a unique capacity to induce,
sustain, and regulate T-cell responses [10, 11]. In tumor set-
ting, DCs circulate through the blood and migrate to tumor
tissues, where they interact with malignant cells. Immature
DCs are particularly eﬃcient in the uptake of tumor-
derived material. DC maturation is induced by tumor-
derived molecules such as heat shock proteins and high-
m o b i l i t y - g r o u pb o x1p r o t e i na sw e l la sp r o i n ﬂ a m m a t o r y
cytokines produced by various tumor-inﬁltrating immune
cells. During maturation DCs migrate from tumor tissues
to T-cell-rich areas of secondary lymphoid organs, where
they activate tumor-reactive CD8+ cytotoxic T lymphocytes
(CTLs) and CD4+ T cells. CD8+ CTLs eﬃciently recognize
and destroy tumor cells, which expose peptides derived
from tumor-associated antigens (TAAs) in the complex
with human leukocyte antigen (HLA) class I molecules
[12]. Clinical studies focusing on the adoptive transfer of
cytotoxic eﬀector cells revealed tumor regression in cancer
patients [13]. CD4+ T cells recognizing peptides in the
context of HLA class II molecules also play an important
role in antitumor immunity [14]. CD4+ T cells improve
the capacity of DCs to induce CTLs by the interaction
b e t w e e nC D 4 0o nD C sa n dC D 4 0l i g a n do na c t i v a t e d
CD4+ T cells. In addition, CD4+ T cells provide help
for the maintenance and expansion of CTLs by secreting
cytokines such as interleukin (IL)-2 and can eradicate tumor
cells directly. Besides their extraordinary capacity to induce
and stimulate T-cell responses, DCs eﬃciently improve the
immunomodulatory and cytotoxic potential of natural killer
cells,whichessentiallycontributetotheeliminationoftumor
cells [15–17]. Furthermore, DCs can also directly mediate
tumor-directed cytotoxicity [18–20]. Owing to their various
antitumor eﬀects, DCs evolved as promising candidates for
vaccination protocols in cancer therapy [21, 22].
3. ProstateCancer-AssociatedAntigensfor
DC-Based Immunotherapy
Based on the crucial role of T cells in the elimination of
tumor cells, much attention has been paied to the identiﬁca-
tion of tumor-associated proteins, that may provide targets
of tumor-reactive T cells, and on the deﬁnition of peptide
motifs within these proteins serving as T-cell epitopes. Here,
we focus on PCa-associated target antigens, which have
already been used for DC-based vaccination trials enrolling
PCa patients. A summary of these CD8+ T cell epitopes is
demonstrated in Table 1.
Prostate-speciﬁc antigen (PSA), a kallikrein-like serin-
protease,isalmostexclusivelyexpressedbyprostateepithelial
cells, can be detected in the majority of PCa tissues, and
represents the most widely used serum marker for diagnosis
and monitoring of PCa [39–42]. The identiﬁcation of
HLA-A2-restricted PSA-derived peptides was driven by in
vitro approaches using peptide-pulsed or RNA-transfected
APCs to activate tumor-reactive CTLs [23–25, 27, 43].
By combining several previously identiﬁed and novel PSA
peptides in an oligopeptide, Correale et al. demonstrated the
possibility of simultaneous induction of CTLs speciﬁc for
diﬀerent epitopes dependent on the HLA repertoire of the
patient [26].
The integral membrane glycoprotein prostate-speciﬁc
membrane antigen (PSMA) represents a marker for normal
prostate cells and can be detected in the majority of prostate
tumors, particularly in undiﬀerentiated, metastatic HRPC
[44, 45]. Several HLA-A2-restricted peptides were shown to
induce tumor-reactive CTL responses in vitro and in vivo
[28, 29].
Prostatic acid phosphatase (PAP) is a glycoprotein with
enzymatic activity, which can be mainly detected in prostate
tissue [46]. Peshwa et al. identiﬁed an HLA-A2-binding,
endogenously generated, immunogenic peptide that induced
tumor-directed CTLs in vitro [30].
Prostate stem cell antigen (PSCA) is a glycosylphos-
phatidylinositol-anchored cell surface glycoprotein, that is
mainly expressed in the prostate [47]. PSCA expression is
detectable in more than 80% of primary PCa samples and
bone metastases. It is increased in both androgen-dependent
and -independent prostate tumors when compared to the
corresponding normal prostate tissues, particularly in carci-
nomas of high stages and Gleason Scores [47, 48]. We and
others identiﬁed an HLA-A2-restricted PSCA peptide, which
induced tumor-reactive CTL responses in vitro [31, 32].
IncreasedfrequenciesofCD8+ Tcellsspeciﬁcforthispeptide
were found in the blood of PCa patients indicating the
relevance of this epitope in vivo [32].
ProsteinrepresentsatransmembraneproteinoftheGolgi
with unique speciﬁcity for normal and malignant prostate
tissues [49, 50]. Our group found abundant expression in
malignant and normal prostate tissues and maintained or
even elevated transcript levels in 87% of the primary tumors
compared to autologous nonmalignant tissue samples [33].
By in vitro stimulation of CD8+ T lymphocytes with peptide-
loaded DCs, we identiﬁed an autochthonously generated,
HLA-A2-presented peptide, that was capable of activating
tumor-reactive CTLs [33].
The gene transient receptor potential (trp)-p8 encodes a
seven-span transmembrane protein with signiﬁcant homol-
ogy to a family of Ca2+ channel proteins [51]. Trp-p8 is
mainly detected in the prostate and shows an overexpression
in PCa of early stages and low grades [34, 51]. We identiﬁed
an HLA-A2-binding peptide, which is able to stimulate
tumor-reactive CTLs in vitro [34].
Potential target structures, which are overexpressed in
tumors of diﬀerent origin including PCa comprise the
human telomerase reverse transcriptase (hTERT), which is
the catalytic subunit of telomerase, and survivin. hTERT is
undetectable in most nontransformed somatic cells but is
expressedinmorethan85%ofhumantumorsincludingPCa
[52]. Several naturally generated CTL epitopes eﬃciently
inducing peptide-speciﬁc and tumor-reactive CTLs in vitro
and in vivo have been described. Thus, the generation
of HLA-A2-restricted hTERT peptide-speciﬁc CTLs, which
are able to lyse hTERT-expressing tumor cells of diverse
histological origin including PCa cells has been reportedClinical and Developmental Immunology 3
Table 1: PCa-associated antigen-derived CD8+ T-cell epitopes used for DC-based immunotherapy.
Antigen HLA restriction element Peptide position Amino acid sequence References
Prostate-speciﬁc antigen (PSA) HLA-A2
146–154 KLQCVDLHV [23, 24]
141–150 FLTPKKLQCV [25, 26]
154–163 VISNDVCAQV [25–27]
Prostate-speciﬁc membrane antigen (PSMA) HLA-A2 4–12 LLHETDSAV [28, 29]
711–719 ALFDIESKV [29]
Prostatic acid phosphatase (PAP) HLA-A2 299–307 ALDVYNGLL [30]
Prostate stem cell antigen (PSCA) HLA-A2 14–22 ALQPGTALL [31, 32]
Prostein HLA-A2 31–39 CLAAGITYV [33]
Transient receptor potential-p8 (Trp-p8) HLA-A2 187–195 GLMKYIGEV [34]
Human telomerase reverse transcriptase (hTERT) HLA-A2 540–548 ILAKFLHWL [35, 36]
Survivin HLA-A2 95–104 ELTLGEFLKL [37, 38]
[35, 36]. In addition, the peptide proved to be immunogenic
in vivo, since immunization of HLA-A2.1 transgenic mice
generated a speciﬁc CTL response [36]. Immunogenicity
in mice could be markedly increased by an amino acid
substitution at an HLA anchoring position [53].
Survivin, an inhibitor of apoptosis, is highly overex-
pressed in many human tumors including PCa, and its
expression correlates with aggressiveness and poor prognosis
of tumor disease [54, 55]. The wide expression in cancer
and the functional role for tumor cell survival make survivin
a promising target for T-cell-based immunotherapy. We
described an endogenously produced HLA-A2-restricted
peptide, which induced speciﬁc CTL responses in vitro
[37]. Speciﬁc T-cell reactivity against this peptide motif
was detected in the peripheral blood of chronic lymphatic
leukemia patients and in tumor-inﬁltrated lymph nodes of
melanoma patients [38].
4. DendriticCell-Based Immunotherapy for
ProstateCancer
DCs play a critical role for the induction of innate and
adaptive antitumor immune responses. Due to their various
antitumor eﬀects, DCs emerged as attractive candidates
for vaccination protocols in cancer therapy (Figure 1).
Animal models demonstrated that TAA-presenting DCs are
capable of inducing protective and therapeutic antitumor
responses [56, 57]. Clinical trials enrolling B-cell lymphoma,
melanoma, or renal cancer patients revealed promising
immunologic and clinical responses of TAA-loaded DCs
administered as a vaccine against cancer [58–61].
In prostate cancer setting, the administration of DCs
pulsed with TAA-derived peptides was well tolerated and
resulted in the induction of immunological and clinical
responses in patients. Thus, a phase-I trial was initiated
to evaluate the vaccination of DCs loaded with PSMA-
derived peptides in HRPC patients [29, 62]. DCs were
generated from monocytes in the presence of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IL-4.
Subsequently, the monocyte-derived DCs were pulsed with
the HLA-A2-restricted PSMA-derived peptides PSM-P1 or
PSM-P2. Nineteen patients received at least two infusions
of up to 2 × 107 peptide-loaded DCs at six- to eight-
week intervals. Treatment was well tolerated except a mild
to moderate transient hypotension. Five partial responders
based on National Prostate Cancer Project criteria and a
>50% reduction of PSA level were observed. Subsequently,
a phase II trial was conducted to further investigate the
therapeutic eﬃciency of PSMA peptide-pulsed DCs [63].
Six infusions of monocyte-derived DCs pulsed with PSM-
P1 and PSM-P2 were administered at six week intervals.
In addition, 17 patients received subcutaneous injections of
GM-CSF.Nine partialresponders basedonNational Prostate
Cancer Project criteria and a >50% reduction of PSA level
were identiﬁed in a group of 33 HRPC patients.
In another clinical study, monocyte-derived DCs pulsed
with a hTERT-derived peptide and keyhole limpet hemo-
cyanin were administered to ﬁve patients with metastatic
HRPC [64]. DCs were subcutaneously injected every other
week for up to six vaccinations. Peptide-reactive T cells were
induced in two patients after vaccination. All four evaluable
patients had stabilization of disease. Recently, we conducted
a clinical study to evaluate the potential of DCs loaded
with a cocktail consisting of HLA-A2-restricted peptides
derived from PSA, PSMA, survivin, prostein, and trpp8
[65]. Immature DCs were generated from monocytes in the
presence of GM-CSF and IL-4. For maturation, DCs were
incubated with GM-CSF, IL-4, IL-1β,I L - 6 ,t u m o rn e c r o -
sis factor (TNF)-α, and prostaglandin E2. Subsequently,
the mature monocyte-derived DCs were pulsed with ﬁve
HLA-A∗0201-restricted TAA-derived peptides. Eight HRPC
patients received four vaccinations of every other week.
Peptide-pulsed DCs were simultaneously injected intrader-
mally and intravenously. One patient displayed a partial
response. Three other patients showed stable disease over 4
to 17 weeks. Three of these four PSA responders exhibited
speciﬁc T-cell responses against prostein, survivin, or PSMA.
In another clinical trial, six HRPC patients were treated
with mature monocyte-derived DCs pulsed with a cocktail
consisting of HLA-A2-restricted peptides derived from PSA,
PSCA, PSMA, and PAP [66]. Treatment was well tolerated.
Three patients displayed speciﬁc T-cell responses against4 Clinical and Developmental Immunology
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Figure 1: DC-based immunotherapeutic strategies for prostate cancer. DCs display a unique capacity to induce and maintain T-cell
responses and emerged as promising candidates for vaccination strategies in prostate cancer therapy. Thus, DCs are loaded with PCa-
associated antigen-derived peptides, protein, or RNA. Due to their high surface expression of HLA-peptide-complexes and costimulatory
molecules, DCs eﬃciently activate and expand CD8+ CTLs and CD4+ Tc e l l s .C D 8 + CTLs possess a profound capability to recognize and
destroy tumor cells. CD4+ T cells enhance the capacity of DCs to induce CTLs by the interaction between CD40 on DCs and CD40 ligand
on activated CD4+ T cells. In addition, they provide help for the maintenance and expansion of CTLs by secreting cytokines and are able to
eradicate tumor cells directly. CTLs: cytotoxic T cells; DCs: dendritic cells; HLA: human leukocyte antigen; IL: interleukin; IFN: interferon;
TCR: T cell receptor; TU: tumor cells.
all antigens. Clinically, DC vaccination was associated with
an increase in PSA doubling time. Thomas-Kaskel et al.
initiated a clinical study to evaluate the vaccination of
DCs pulsed with PSA- and PSMA-derived peptides in 12
patients with hormone- and chemotherapy-refractory PCa
[67]. Patients received four vaccinations with a median
of 2.7 × 107 peptide-loaded mature monocyte-derived
DCs subcutaneously in biweekly intervals. Six patients
had stable disease and ﬁve patients developed delayed-
type hypersensitivity (DTH) reactions. DTH-positivity was
associated with superior survival. A signiﬁcant correlation
between DTH reactions and progression-free survival was
not observed. Hildenbrand et al. conducted a clinical trial
enrolling 12 HRCP patients, which was based on the
combination of interferon (IFN)-γ and mature monocyte-
derived DCs pulsed with three diﬀerent HLA-A2-restricted
PSA peptides [68]. Treatment consisted of the subcuta-
neous injection of IFN-γ followed by three intracutaneous
administrations of 2 × 106 peptide-loaded DCs. Vaccination
was applied four times at three-week intervals. No severe
side eﬀects were observed. One patient displayed a partial
response showing regression of lymph node metastases,
four patients showed stable disease, one patient exhibited
a mixed response, and six patients displayed progressive
disease.
Further clinical trials evaluated immunological and
therapeuticeﬃciencyof protein-loaded DCs in PCa patients.
Thus,Fongetal.administeredDCsloadedwithrecombinant
murine PAP protein to 21 patients with metastatic PCa
[69]. Patients received two injections monthly with a mean
dose of 11,2 × 106 cells per vaccination. Treatment was
well tolerated. All patients developed T-cell immunity to
mouse PAP and 11 patients to the homologous self-antigen
human PAP. Six patients displayed clinical stabilization of
their previously progressing PCa as determined by PSA level
monitoring, computerized tomography, and bone scans. All
these patients developed T-cell proliferation in response to
human PAP. Another clinical trial was performed to evaluate
the eﬃciency of mature monocyte-derived DCs pulsed with
human recombinant PSA protein for the treatment of PCa
patients in biochemical relapse after radical prostatectomy
[70]. Twenty-four patients received nine administrations of
PSA-loaded DCs by combined intravenous, subcutaneous,
and intradermal routes over 21 weeks. No severe side eﬀects
were observed and 11 patients exhibited a transient PSA
decrease.
A particular promising immunotherapeutic strategy for
advanced PCa patients is based on the administration of
APCs pre-exposed in vitro to PA2024, a fusion protein con-
sisting of human GM-CSF and PAP (APC8015, sipuleucel-T,Clinical and Developmental Immunology 5
Provenge). To generate sipuleucel-T, autologous peripheral
blood mononuclear cells including APCs such as DCs were
collected by two sequential buoyant density centrifugation
steps and incubated with PA2024. Small et al. conducted
sequential phase I and phase II trials including 31 HRPC
patients to determine the safety and eﬃcacy of sipuleucel-
T[ 71]. Patients were treated intravenously with sipuleucel-
T on weeks 0, 4, 8, and 24. Treatment was well tolerated.
No patient had pre-existing T-cell responses or antibodies
to PAP. After treatment, 38% of patients developed a T-
cell response to PAP and 53% of patients had antibodies.
Three patients had a more than 50% decline in PSA level
and additional 3 patients displayed 25% to 49% decreases
in PSA. In another phase II trial, 21 HRPC patients were
vaccinated with sipuleucel-T [72]. In this study, the vaccine
was administered intravenously twice, on weeks 0 and 2. The
median number of cells was 2.7 × 109 for the ﬁrst infusion
and 3.2 × 109 for the second infusion. Subsequently, patients
received three subcutaneous injections of PA2024 at weeks
4, 8, and 12. Two patients exhibited a 25% to 50% transient
decrease in PSA level. For a third patient, PSA dropped
to undetectable levels by week 24. The PSA level remained
undetectable for 52 months and the metastatic adenopathy
resolved.
Rini et al. performed a clinical trial, which was based
on the administration of sipuleucel-T and bevacizumab
to 22 patients with recurrent PCa after deﬁnitive local
therapy[73].Bevacizumabisarecombinantantibodyagainst
vascular endothelial growth factor, that represents a proan-
giogenic protein with inhibitory eﬀects on APCs. Patients
received sipuleucel-T intravenously on weeks 0, 2, and 4
and bevacizumab on weeks 0, 2, and 4 and every two weeks
thereafteruntiltoxicityordiseaseprogressionwereobserved.
Nine patients displayed a decrease of PSA, ranging from 6%
to 72%.
Following the results of the previous studies, a phase III
study (D9901) enrolling 127 metastatic HRPC patients was
conducted to determine the safety and therapeutic eﬃciency
of sipuleucel-T in a placebo-controlled trial [74]. Patients
were randomized to receive three infusions of the vaccine or
placebo every two weeks with primary endpoint of time to
disease progression. The median time to disease progression
was not statistically signiﬁcant at 11.7 weeks in the vaccine
group compared with 10.0 weeks in the placebo group.
However, a statistically signiﬁcant increase in median overall
survival was observed (25.9 months in the vaccine group;
21,4 months in the placebo group).
More recently, Higano et al. performed an integral data
analysis of the formerly described phase III study (D9901)
and a second phase III trials (D9902A), which was also based
on the administration of sipuleucel-T to HRPC patients
[75]. Altogether, 225 patients were randomized to receive
three infusions of sipuleucel-T (147 patients) or placebo
(78 patients) every two weeks. Of the 147 patients in
the sipuleucel-T arms, 5 patients showed a PSA reduction
of >50% and two additional patients of >25%. Patients
randomized to sipuleucel-T had a 21% reduction in the risk
of disease progression and a 33% reduction in the risk of
death compared with patients randomized to placebo. The
median survival was of 23,2 months in the sipuleucel-T
arms and 18,9 months in the placebo arms. The percentage
of patients alive at 36 months was 33% in the sipuleucel-
T arms and 15% in the placebo arms. Treatment was well
tolerated. The overall incidence of adverse events was similar
between patients treated with sipuleucel-T and patients
treated with placebo. The most common adverse events were
chills, pyrexia, headache, asthenia, dyspnea, vomiting, and
tremor. Taken together, the integrated results of D9901 and
D9902A demonstrate a survival beneﬁt for patients treated
with sipuleucel-T compared to patients treated with placebo.
To further conﬁrm the therapeutic eﬃciency of sipuleucel-T
another randomised, placebo-controlled, multicenter phase
III trial enrolling 512 patients with metastatic HRPC was
conducted [76]. Patients on the sipuleucel-T treatment arm
experienced a relative reduction of 22% in the risk of death
compared with the placebo group. The median survival was
25,8 months in the sipuleucel-T group and 21,7 months in
the placebo group. Based on these promising clinical results,
the United States Food and Drug Administration recently
approved sipuleucel-T for the treatment of asymptomatic or
minimally symptomatic, metastatic HRPC.
Further DC-based immunotherapeutic strategies for
prostate cancer were evaluated in clinical trials. Thus, the
potential of RNA-transfected DCs for PCa therapy was
investigated. In this context, Heiser et al. vaccinated PSA
RNA-transfected DCs to 13 metastatic PCa patients [77].
DCs were generated from monocytes in the presence of
GM-CSF and IL-4 and subsequently transfected with PSA
RNA. The PSA RNA-transfected DCs were administered at
three escalating dose levels. Dose escalation was performed
through an intravenous route with 1 × 107,3× 107,o r5×
107 cellsappliedatweeks2,4,and6.Foroptimization,acon-
comitantdoseof1 ×107 cellswasgivenintradermallyateach
vaccination cycle. Induction of PSA-speciﬁc T-cell responses
was found in all evaluated patients. Six of seven evaluated
patients displayed a signiﬁcant decrease in the log slope PSA.
In another clinical trial, hTERT RNA-transfected DCs were
administered to 20 metastatic PCa patients [78]. Vaccination
resulted in an expansion of hTERT-speciﬁc T cells in 19
patients,wasassociatedwithareductionofPSAvelocity, and
a molecular clearance of circulating tumor cells. Mu et al.
conductedaclinicalstudyenrolling20HRPCpatients,which
was based on the administration of monocyte-derived DCs
transfected with RNA from allogeneic PCa cell lines [79].
Each patient received at least four weekly injections with 2
× 107 transfected DCs either intranodally or intradermally.
Thirteen of 19 patients that completed vaccination displayed
a decrease in log slope PSA.
Another vaccination strategy for prostate cancer is based
on the administration of c-fms-like tyrosine kinase 3 (Flt3)
ligand. This immunostimulatory agent eﬃciently promotes
the diﬀerentiation and expansion of DCs in vitro and in
vivo. Higano et al. conducted a trial evaluating the eﬃciency
of Flt3 ligand in HRPC patients [80]. Treatment was well
tolerated. Flt3 ligand application resulted in a marked
i n c r e a s eo fD Cn u m b e ri nt h ep e r i p h e r a lb l o o d .E l e v e no f3 1
patients showed a decrease or only a minor increase (<25%)
in PSA levels.6 Clinical and Developmental Immunology
5. Conclusion
DCs play a crucial role for the induction of innate and
adaptive antitumor immune responses. Thus, they eﬃ-
ciently activate and expand tumor-reactive CD8+ CTLs and
CD4+ T cells. In addition, DCs can markedly improve the
immunomodulatory and cytotoxic potential of natural killer
cells and can directly mediate tumor-directed cytotoxicity.
Due to their various antitumor eﬀects, DCs emerged as
promising candidates for the treatment of PCa patients.
Consequently, several clinical trials enrolling PCa patients
were conducted, which were based on the administration of
DCs pulsed with TAA-derived peptides, protein, or RNA.
These studies demonstrated that DC-based immunother-
apeutic strategies represent safe and feasible concepts for
the induction of immunological and clinical responses in
PCa patients. Recently, sipuleucel-T consisting of PA2024
fusion protein-loaded APCs was approved by the United
States Food and Drug Administration for the treatment
of asymptomatic or minimally symptomatic, metastatic
HRPC. Despite these promising clinical eﬀects the eﬃciency
of the various DC-based treatment modalities for many
patients with advanced PCa is still limited. Therefore,
further improvement is required, which may be achieved by
combining DC-based vaccination strategies with antibody-,
radio-, hormone-, chemo-, or antiangiogenic therapy.
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